Impact of acquired Factor XIII de?ciency on major bleeding events and transfusion requirements in veno-arterial ECMO patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00036363

Enrollment

600

Registered

2025-03-07

Start date

2024-01-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acquired Factor XIII de?ciency during veno-arterial ECMO treatment

Interventions

Group 1: In this study, all VA-ECMO patients who has their Factor XIII level measure at least once were included in the analysis. These patients should divide into two groups: • Factor XIII deficiency

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: VA-ECMO treatment

Exclusion criteria

Exclusion criteria: - age < 18 years - no Factor XIII measurement - repeated ECMO therapies - incomplete data sets

Design outcomes

Primary

Measure	Time frame
Frequency of major bleeding events and transfusion requirements (packed red blood cell [PRBC], fresh frozen plasma [FFP], platelet concentrate [PC]) between the two study groups	—

Secondary

Measure	Time frame
Hospital mortality rate with reasons of mortality, length of VA-ECMO, ICU and hospital treatment, application rate of Factor XIII concentrates between the two study groups	—

Countries

Germany

Contacts

Public ContactSebastian Blecha

Universitätsklinikum Regensburg, Klinik für Anästhesiologie

Sebastian.Blecha@ukr.de0941-944 7801

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026